According to our results, Aβ deposition area and Aβ plaques in the AD-EVs-inhibitor-sh-BACE1 group were dramatically reduced relative to those in the AD-EVs-inhibitor-sh-NC group (p < 0.001) (Figure 6C). Here, BACE1 is linked to Alzheimer disease.